Art No.: YLA4551HU Application: ELISA Size: 96T/48T Reaction: Human Methodsandwich Detection range0.5ng/ml300ng/ml Sensitivity0.23ng/ml Assay length1-4.5Hours Detection Wavelengt450nm Research AreaImmunology Priceinquiry Quality guarantee periodfor 12 months Introduction INTENDED USE The kit is a sandwich enzyme immunoassay for in vitro quantitative measurement of this index in serum, plasma,tissue homogenates,cell lysates,cell culture supernates and other biological fluids
Matsuba K, Wright JL, Wiggs BR, Pare PD, Hogg JC
Donahue, A
Disclosures: Lorenza Rimassa: Jazz Pharmaceuticals, MSD, Nerviano Medical Sciences: Consultant, Roche, Servier, Taiho Oncology, Zymeworks: Consultant, AstraZeneca: Travel expenses, Agios, AstraZeneca, BeiGene, Eisai, Exelixis: Grant/Research Support, Fibrogen, Incyte, Ipsen, Lilly, MSD, Nerviano Med Sciences: Grant/Research Support, AbbVie, AstraZeneca, Basilea, Bayer, Elevar Therapeutics: Consultant, Exelixis, Genenta, Hengrui, Incyte, Ipsen, IQVIA: Consultant, AstraZeneca, Bayer, BMS, Guerbet: Speaking and Teaching, Incyte, Ipsen, Roche, Servier: Speaking and Teaching, Agios, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen: Grant/Research Support, Incyte, Ipsen, Lilly, MSD, Nerviano Medical Sciences: Grant/Research Support, Roche, Servier, TransThera Sciences, Zymeworks: Grant/Research Support, Stephen Chan: MSD: Honoraria recipient, research grants, Ipsen: Honoraria recipient, research grants, Astra-Zeneca: Speaking and Teaching, Eisai: Speaking and Teaching, Roche: Speaking and Teaching, Bruno Sangro: Nothing to Disclose, George Lau: Nothing to Disclose, Masatoshi Kudo: Nothing to Disclose, Valeriy Breder: Roche: Speaking and Teaching, AstraZeneca: Speaking and Teaching, EISAI: Speaking and Teaching, Bayer: Speaking and Teaching, Swixx BioPharma: Speaking and Teaching, Maria Varela: Boston: Speaking and Teaching, Astra Zeneca: Consultant, Roche: Consultant, Oxana Crysler: Nothing to Disclose, Mohamed Bouattour: Bayer: Consultant, AstraZeneca: Consultant, MSD: Consultant, BMS: Consultant, SIRTEX Medical: Consultant, ROCHE: Consultant, Bayer: Advisor, Tu Van Dao: Nothing to Disclose, Adilson Faccio: Nothing to Disclose, Junji Furuse: Astra Zeneca: Speaking and Teaching, Ono Pharma: Speaking and Teaching, Chugai Pharma: Speaking and Teaching, Eisai: Speaking and Teaching, Servier: Speaking and Teaching, MSD: Advisor, Novartis Pharma: Speaking and Teaching, Takeda: Speaking and Teaching, Taiho Pharma: Speaking and Teaching, Daiichi Sankyo: Speaking and Teaching, Incyte Biosciences: Speaking and Teaching, J-Pharma: Advisor, Astellas: Advisor, Onco Therapy Science: Advisor, Delta-Fly-Pharma: Advisor, TME Therap: Advisor, Long-Bin Jeng: Nothing to Disclose, Yoon Koo Kang: Nothing to Disclose, Robin Kate Kelley: Astra Zeneca: Grant/Research Support, Bayer: Grant/Research Support, Eli Lilly: Grant/Research Support, Exelixis: Grant/Research Support, Genentech/Roche: Grant/Research Support, Kinnate: Consultant, Merck: Grant/Research Support, Partner Therapeutics: Grant/Research Support, Regeneron: Consultant, Agios: Grant/Research Support, BMS: Grant/Research Support, QED: Grant/Research Support, Tyra: Grant/Research Support, Taiho: Grant/Research Support, Surface: Grant/Research Support, Servier: Grant/Research Support, GSK: Consultant, moderna: Consultant, J Pharma Inc.: Consultant, Relay Therapeutics: Grant/Research Support, Michael Paskow: Nothing to Disclose, Mallory Makowsky: Nothing to Disclose, Di Ran: Nothing to Disclose, Alejandra Negro: Nothing to Disclose, Ghassan Abou-Alfa: Agenus, Arcus, Astra Zeneca, BioNtech, BMS, Elicio, Genentec: Grant/Research Support, Abbvie, Alligator Astra Zeneca, Autem, Berry Genomics, BioNt: Consultant 1850 IMMUNE-RELATED LIVER INJURY IS A GOOD PROGNOSTIC FACTOR IN PATIENTS WITH HEPATOCELLULAR CARCINOMA UNDER ATEZOLIZUMAB PLUS BEVACIZUMAB THERAPY Tai-Chi Wu 1 Wei Teng 1 Po-Ting Lin 1 Eric Yi-Liang Shen 1 Chung-Wei Su 1 Yi-Chung Hsieh 1 Wei-Ting Chen 1 Tsung-Han Wu 1 Chen-Chun Lin 1 Chun-Yen Lin 1 Shi-Ming Lin 1 , 1 Linkou Chang Gung Memorial Hospital Background: Atezolizumab plus bevacizumab therapy is the standard first-line therapy for unresectable hepatocellular carcinoma (HCC), and immune-related liver injury (IrLI) is commonly observed in these treated patients, especially with underlying chronic liver disease
